Humira® is the commercial brand name of Adalimumab Solution for Injection, a fully human recombinant anti-TNF-α monoclonal antibody developed by AbbVie. It specifically binds and neutralizes tumor necrosis factor-alpha (TNF-α), blocks inflammatory signal transduction, and suppresses abnormal autoimmune inflammatory responses…
Mayzent® is the commercial brand name of Siponimod Tablets, an orally active sphingosine-1-phosphate receptor modulator developed by Novartis. It selectively binds to S1P receptors on lymphocytes to reduce lymphocyte infiltration into the central nervous system and alleviate neuroinflammatory injury. Main…
Rinvoq® is the commercial brand name of Upadacitinib Sustained-release Tablets, an orally active selective Janus kinase (JAK) inhibitor developed by AbbVie. It preferentially inhibits JAK1 to block the signal transduction of multiple pro-inflammatory cytokines and suppress abnormal inflammatory immune responses.…
Entyvio® is the commercial brand name of Vedolizumab for Injection, a humanized monoclonal antibody against α4β7 integrin developed by Takeda. It selectively blocks the binding of α4β7 integrin on lymphocytes to mucosal addressin cell adhesion molecule-1, inhibiting lymphocyte migration to…
Aubagio® is the commercial brand name of Teriflunomide Tablets, an orally active immunomodulatory agent developed by Sanofi. It inhibits dihydroorotate dehydrogenase to suppress the proliferation of activated T and B lymphocytes, reducing autoimmune inflammatory damage in the central nervous system.…
Xeljanz® is the commercial brand name of Tofacitinib Citrate Tablets, an orally active Janus kinase (JAK) inhibitor developed by Pfizer. It selectively inhibits JAK family enzymes to block multiple pro-inflammatory cytokine signaling pathways, suppressing excessive immune and inflammatory responses. Main…
Sotyktu® is the commercial brand name of Deucravacitinib Tablets, an orally active selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb. It selectively binds to the TYK2 JH2 domain to inhibit TYK2-mediated signaling, regulates multiple pro-inflammatory cytokine pathways,…
Rezurock® is the commercial brand name of Belumosudil Mesylate Tablets, an orally active selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor developed by Sanofi. It selectively inhibits ROCK2, modulates Th17/Treg immune balance, reduces pro-inflammatory cytokine release and alleviates immune-mediated tissue fibrosis…
Benlysta® is the commercial brand name of Belimumab powder for concentrate for solution for infusion, a human monoclonal antibody developed by GSK. It binds to soluble B lymphocyte stimulator (BLyS), inhibits the survival of autoreactive B cells, lowers the level…
Olumiant® is the commercial brand name of Baricitinib Tablets, an orally active selective Janus kinase (JAK) inhibitor developed by Eli Lilly. It selectively inhibits JAK1 and JAK2, regulates multiple pro-inflammatory cytokine signaling pathways, and suppresses persistent inflammatory responses. Main IndicationsTreatment…